ArticleVeterinary research2014
The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later.
Article in Veterinary research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- World Association for Veterinary Dermatology Consensus Statement for Diagnosis, and Evidence-Based Clinical Practice Guidelines for Treatment and Prevention of Canine Leishmaniosis.Veterinary dermatology · 2025Guideline
- How Effective Are the Canine Visceral Leishmaniasis Vaccines Currently Being Tested in Dogs? A Systematic Review and Meta-Analysis.Parasite immunology · 2025Pooled it
- Field Evaluation of Two Different Treatment Approaches and Their Ability to Control Fleas and Prevent Canine Leishmaniosis in a Highly Endemic Area.PLoS neglected tropical diseases · 2016Trial
- A randomised, double-blind, controlled efficacy trial of the LiESP/QA-21 vaccine in naïve dogs exposed to two leishmania infantum transmission seasons.PLoS neglected tropical diseases · 2014Trial
- Updated Canine Leishmaniosis Working Group recommendations for leishmaniosis in dogs: Q&A on clinical management.Parasites & vectors · 2026Review
- Overview of Commercial Vaccines Against Canine Visceral Leishmaniasis: Current Landscape and Future Directions.Pathogens (Basel, Switzerland) · 2025Review
- An update on recombinant vaccines against leishmaniasis.The Indian journal of medical research · 2024Review
- Immunoproteomics and phage display in the context of leishmaniasis complexity.Frontiers in immunology · 2023Review
- Canine Leishmaniasis: Update on Epidemiology, Diagnosis, Treatment, and Prevention.Veterinary sciences · 2022Review
- Antibodies elicited by the CaniLeish® vaccine: long-term clinical follow-up study of dogs in Spain.Parasitology research · 2021Article
- Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines.Frontiers in veterinary science · 2021Review
- Latest trends in L. infantum infection in dogs in Spain, Part II: current clinical management and control according to a national survey of veterinary practitioners.Parasites & vectors · 2020Article
- The Delay in the Licensing of Protozoal Vaccines: A Comparative History.Frontiers in immunology · 2020Review
- Peptide-based vaccine successfully induces protective immunity against canine visceral leishmaniasis.NPJ vaccines · 2019Article
- Assessment of Vaccine-Induced Immunity Against Canine Visceral Leishmaniasis.Frontiers in veterinary science · 2019Review
- Safety Analysis ofThe American journal of tropical medicine and hygiene · 2018Article
- Peptide Vaccines for Leishmaniasis.Frontiers in immunology · 2018Review
- Article
- Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.PLoS neglected tropical diseases · 2016Article
- Application of rapid in vitro co-culture system of macrophages and T-cell subsets to assess the immunogenicity of dogs vaccinated with live attenuated Leishmania donovani centrin deleted parasites (LdCen-/-).Parasites & vectors · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Control of canine leishmaniasis is an important objective for the benefit of dogs living in or visiting endemic areas and for public health because of the zoonotic nature of this disease. Resistance or susceptibility to developing canine leishmaniasis after exposure to Leishmania infantum is primarily determined by the ability of the immune system to develop an appropriate Th1-dominated specific response to the parasite. For this reason there is a need for effective canine vaccines that can decrease the number of dogs developing progressive infections. In this study, we followed the impact of the LiESP/QA-21 canine vaccine (composed of excreted-secreted proteins of L. infantum and the QA-21 saponin adjuvant), recently launched commercially in Europe, on selected humoral and cellular immune parameters following an infectious intravenous challenge with L. infantum promastigotes administered one year after the primary vaccine course. We also followed parasitological parameters to determine the parasitological status of the challenged dogs. In contrast to controls, vaccinated dogs retained significantly stronger cell-mediated immune responses against the parasite despite a virulent challenge and had significantly lower mean parasite burdens at the end of the study, associated with a lower probability of developing active infections. These results confirm that the immune responses generated by vaccination with LiESP/QA-21 are still effective against an intravenous challenge one year after the primary vaccine course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.